Amyloid fibrils formed by selective N-, C-terminal sequences of mouse apolipoprotein A-II

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1794, Issue 10, 2009, Pages 1517-1529

  Sawashita, Jinko ^a   Kametani, Fuyuki ^b   Hasegawa, Kazuhiro ^c   Tsutsumi Yasuhara, Shinobu ^c   Zhang, Beiru ^a,d   Yan, Jingmin ^a   Mori, Masayuki ^a   Naiki, Hironobu ^c   Higuchi, Keiichi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c Department of Pathological Sciences   (Japan)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein A II; Fibril conformation; Mouse senile amyloidosis

Indexed keywords

ALANINE; AMYLOID; APOLIPOPROTEIN A2; GLYCINE; PROLINE; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; IN VITRO STUDY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN POLYMERIZATION; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN A-II; CIRCULAR DICHROISM; HYDROGEN-ION CONCENTRATION; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

MUS;

EID: 69449094174     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.06.028     Document Type: Article

References (62)

1. Westermark P. The pathogenesis of amyloidosis. Am. J. Pathol. 152 (1998) 1125-1127
2. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., Masters C.L., Merlini G., Saraiva M.J., and Sipe J.D. Amyloid fibril protein nomenclature - 2002. Amyloid 9 (2002) 197-200
3. Taylor J.P., Hardy J., and Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 296 (2002) 1991-1995
4. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81 (2003) 678-699
5. Yazaki M., Varga J., Dyck J.B., and Benson M.D. A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis. Amyloid 9 (2002) 268-271
6. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6 (2004) 1054-1061
7. Hasegawa K., Yamaguchi I., Omata S., Gejyo F., and Naiki H. Interaction between Aβ(1-42) and Aβ(1-40) in Alzheimer's β-amyloid fibril formation in vitro. Biochem. 38 (1999) 15514-15521
8. 2-microgloblin by Achromobacter protease I. J. Biol. Chem. 277 (2002) 1310-1315
9. Modler A.J., Fabian H., Sokolowski F., Lutsch G., Gast K., and Damaschun G. Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid 11 (2004) 215-231
10. Kammerer R.A., Kostrewa D., Zurdo J., Detken A., Garcia-Echeverria C., Green J.D., Müller S.A., Meier B.H., Winkler F.K., Dobson C.M., and Steinmetz M.O. Exploring amyloid formation by a de novo design. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4435-4440
11. Nguyen H.D., and Hall C.K. Kinetics of fibril formation by polyalanine peptides. J. Biol. Chem. 280 (2005) 9074-9082
12. Kostner G.M., Patsch D.R., Sailer S., Braunsteiner H., and Holasek A. Polypeptide distribution of the main lipoprotein density classes separated from human plasma by rate zonal ultracentrifugation. Eur. J. Biochem. 45 (1974) 611-621
13. Schultz J.R., Gong E.L., McCall M.R., Nichols A.V., Clift S.M., and Rubin E.M. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J. Biol. Chem. 267 (1992) 21630-21636
14. Gong E.L., Stoltzfus L.J., Brion C.M., Murugesh D., and Rubin E.M. Contrasting in vivo effects of murine and human apolipoprotein A-II. J. Biol. Chem. 271 (1996) 5984-5987
15. Warden C.H., Daluiski A., Bu X., Purcell-Huynh D.A., De Meester C., Shieh B.H., Puppione D.L., Gray R.M., Reaven G.M., Chen Y.D., Rotter J.I., and Lusis A.J. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10886-10890
16. Holvoet P., Danloy S., Deridder E., Lox M., Bernar H., Dhoest A., and Collen D. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice. J. Clin. Invest. 102 (1998) 379-385
17. Hedrick C.C., Castellani L.W., Wong H., and Lusis A.J. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J. Lipid Res. 42 (2001) 563-570
18. SAM) from mouse serum. J. Biol. Chem. 261 (1986) 12834-12840
19. Higuchi K., Yonezu T., Tsunasawa S., Sakiyama F., and Takeda T. The single proline-glutamine substitution at position 5 enhances the potency of amyloid fibril formation of murine apoA-II. FEBS Lett. 207 (1986) 23-27
20. SAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 60 (1991) 231-238
21. Kitagawa K., Wang J., Matsushita T., Kogishi K., Hosokawa M., Fu X., Guo Z., Mori M., and Higuchi K. Polymorphisms of mouse apolipoprotein A-II: seven alleles found among 41 inbred strains of mice. Amyloid 10 (2003) 207-214
22. 5-Gln) presents only in the senile amyloidosis prone SAM-P/1 and SAM-P/2 mice. Lab. Invest. 57 (1987) 65-70
23. Higuchi K., Kitagawa K., Naiki H., Hanada K., Hosokawa M., and Takeda T. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem. J. 279 (1991) 427-433
24. Higuchi K., Kogishi K., Wang J., Chen X., Chiba T., Matsushita T., Hoshii Y., Kawano H., Ishihara T., Yokota T., and Hosokawa M. Fibrilization in mouse senile amyloidosis is fibril conformation-dependent. Lab. Invest. 78 (1998) 1535-1542
25. Xing Y., Nakamura A., Korenaga T., Guo Z., Yao J., Fu X., Matsushita T., Kogishi K., Hosokawa M., Kametani F., Mori M., and Higuchi K. Induction of protein conformational change in mouse senile amyloidosis. J. Biol. Chem. 277 (2002) 33164-33169
26. c). Lab. Invest. 87 (2007) 633-643
27. Palha J.A., Ballinari D., Amboldi N., Cardoso I., Fernandes R., Bellotti V., Merlini G., and Saraiva M.J. 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am. J. Pathol. 156 (2000) 1919-1925
28. Korth C., May B.C., Cohen E.E., and Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9836-9841
29. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Franser P.E., Mount H.T., Przybylski M., and George-Hyslop St.P. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8 (2002) 1263-1269
30. Ono K., Hasegawa K., Yoshiike Y., Takashima A., Yamada M., and Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro. J. Neurochem. 81 (2002) 434-440
31. Townsend K.P., and Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19 (2005) 1562-1601
32. Frenkel D., Maron R., Burt D.S., and Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 23 (2005) 462-469
33. Green N.S., Foss T.R., and Kelly J.W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14545-15550
34. Naiki H., Higuchi K., Hosokawa M., and Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal. Biochem. 177 (1989) 244-249
35. Ban T., Hamada D., Hasegawa K., Naiki H., and Goto Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 278 (2003) 16462-16465
36. Korenaga T., Fu X., Xing Y., Matsusita T., Kuramoto K., Syumiya S., Hasegawa K., Naiki H., Ueno M., Ishihara T., Hosokawa M., Mori M., and Higuchi K. Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils. Am. J. Pathol. 164 (2004) 1597-1606
37. Kametani F. Secretion of long Aβ-related peptides processed at e{open}-cleavage site is dependent on the α-secretase pre-cutting. FEBS Lett. 570 (2004) 73-76
38. 2-microglobulin-related amyloid fibrils at a neutral pH. Biochem. 43 (2004) 11075-11082
39. 2-microglobulin-related amyloid fibrils at a neutral pH. J. Am. Soc. Nephrol. 15 (2004) 126-133
40. Higuchi K., Kogishi K., Wang J., Xia C., Chiba T., Matsushita T., and Hosokawa M. Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils. Biochem. J. 325 (1997) 653-659
41. Wood S.J., Wetzel R., Martin J.D., and Hurle M.R. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochem. 34 (1995) 724-730
42. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castaño E.M., and Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications of Alzheimer's therapy. Nat. Med. 4 (1998) 822-826
43. Satyal S.H., Schmidt E., Sondheimer N., Lindquist S., Kramer J.M., and Morimoto R. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5750-5755
44. Perutz M.F., Pope B.J., Wanker E.E., and Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid β-peptide of amyloid plaques. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5596-5600
45. +] prion in yeast and aggregation of Sup35 in vitro. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12934-12939
46. Jarrett J.T., and Lansbury P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73 (1993) 1055-1058
47. Fu L., Matsuyama I., Chiba T., Xing Y., Korenaga T., Guo Z., Fu X., Nakayama J., Mori M., and Higuchi K. Extrahepatic expression of apolipoprotein A-II in mouse tissues: possible contribution to mouse senile amyloidosis. J. Histochem. Cytochem. 49 (2001) 739-747
48. Glenner G.G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N. Eng. J. Med. 302 (1980) 1283-1292
49. Andreola A., Bellotti V., Giorgetti S., Mangione P., Obici L., Stoppini M., Torres J., Monzani E., Merlini G., and Sunde M. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. J. Biol. Chem. 278 (2003) 2444-2451
50. Hasegawa K., Tsutsumi-Yasuhara S., Ookoshi T., Ohhashi Y., Kimura H., Takahashi N., Yoshida H., Miyazaki R., Goto Y., and Naiki H. Growth of β2-microglobulin-related amyloid fibrils by non-esterified fatty acids at a neutral pH. Biochem. J. 416 (2008) 307-315
51. McGowan D.P., Van Roon-Mom W., Holloway H., Bates G.P., Mangiarini L., Cooper G.J., Faull R.L., and Snell R.G. Amyloid-like inclusions in Huntington's disease. Neurosci. 100 (2000) 677-680
52. Higuchi K., Wang J., Kitagawa K., Matsushita T., Kogishi K., Naiki H., Kitado H., and Hosokawa M. Accelerated senile amyloidosis induced by amyloidogenic apoA-II gene shortens the life span of mice but does not accelerate the rate of senescence. J. Gerontol. A Biol. Sci. Med. Sci. 51 (1996) B295-B302
53. Chiba T., Kogishi K., Wang J., Xia C., Matsushita T., Miyazaki J., Saito I., Hosokawa M., and Higuchi K. Mouse senile amyloid deposition is suppressed by adenovirus-mediated overexpression of amyloid-resistant apolipoprotein A-II. Am. J. Pathol. 155 (1999) 1319-1326
54. 2 mice. Biochem. Genet. 42 (2004) 347-363
55. Kumar M.S., Carson M., Hussain M.M., and Murthy H.M. Structures of apolipoprotein A-II and a lipid-surrogate complex provide insights into apolipoprotein-lipid interactions. Biochem. 41 (2002) 11681-11691
56. Zhang H., Sawashita J., Fu X., Korenaga T., Yan J., Mori M., and Higuchi K. Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods. FASEB J. 20 (2006) 1012-1014 Epub 2006 Mar 20
57. Yanagisawa K., Okada A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995) 1062-1066
58. Tashima Y., Oe R., Lee S., Sugihara G., Chamners E.J., Takahashi M., and Yamada T. The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid β-peptide from liposomes prepared from brain membrane-like lipids. J. Biol. Chem. 279 (2004) 17587-17595
59. Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C.A., Selkoe D.J., Naiki H., and Yanagisawa K. A seed for Alzheimer amyloid in the brain. J. Neurosci. 24 (2004) 4894-4902
60. Yamamoto N., Hirabayashi Y., Amari M., Yamaguchi H., Romanov G., Van Nostrand W.E., and Yanagisawa K. Assembly of hereditary amyloid β-protein variants in the presence of favorable gangliosides. FEBS Lett. 579 (2005) 2185-2190
61. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson J.E., and Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92 (2005) 171-182
62. Zhu M., and Fink A.L. Lipid binding inhibits α-synuclein fibril formation. J. Biol. Chem. 278 (2003) 16873-16877